News
TWST
15.82
-7.21%
-1.23
Biopharma Exposure In SVB Financial Group And Investor Strategy
Seeking Alpha · 6d ago
Twist Bioscience Announced An Integrated Offering Of Antibody Discovery Services Available To Customers
Benzinga · 03/09 13:23
BRIEF-Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches
Reuters · 03/09 13:09
Twist Bioscience: Biopharma And Data Storage Are Underappreciated
Seeking Alpha · 03/08 16:36
Twist Bioscience Enters Oversold Territory (TWST)
NASDAQ · 03/01 22:20
23andMe Looking Promising For The Long Term
Seeking Alpha · 03/01 06:10
Look Under The Hood: ESGV Has 16% Upside
NASDAQ · 02/27 13:09
Hot Stocks: DAN slumps on earnings news; HSBC rises; TSLA reportedly eyeing SGML; TWST hits 52-week low
Seeking Alpha · 02/21 22:53
Twist Bioscience (TWST) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
NASDAQ · 02/20 14:55
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
NASDAQ · 02/17 16:08
Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery
Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery
MT Newswires · 02/14 13:55
BRIEF-Twist Bioscience Announces Technology Early Access Of Enhanced Whole Genome Sequencing Solution At AGBT
Reuters · 02/07 13:07
Goldman Sachs Keeps Their Hold Rating on Twist Bioscience (TWST)
TipRanks · 02/06 16:25
Goldman Sachs Maintains Neutral on Twist Bioscience, Lowers Price Target to $43
Benzinga · 02/06 15:06
Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $29
Benzinga · 02/06 13:23
J.P. Morgan Keeps Their Sell Rating on Twist Bioscience (TWST)
TipRanks · 02/06 12:06
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $32
Benzinga · 02/06 11:54
--Goldman Sachs Adjusts Price Target on Twist Bioscience to $43 From $50, Maintains Neutral Rating
--Goldman Sachs Adjusts Price Target on Twist Bioscience to $43 From $50, Maintains Neutral Rating
MT Newswires · 02/06 11:15
--Barclays Adjusts Price Target on Twist Bioscience to $32 From $37, Maintains Overweight Rating
--Barclays Adjusts Price Target on Twist Bioscience to $32 From $37, Maintains Overweight Rating
MT Newswires · 02/06 10:19
--Baird Adjusts Price Target on Twist Bioscience to $29 From $33, Maintains Outperform Rating
--Baird Adjusts Price Target on Twist Bioscience to $29 From $33, Maintains Outperform Rating
MT Newswires · 02/06 08:53
More
Webull provides a variety of real-time TWST stock news. You can receive the latest news about Twist Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About TWST
Twist Bioscience Corporation is a synthetic biology and genomics company. The Company has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a technology that provides a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The Company utilizes its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. It consists of two product lines, synthetic biology tools and NGS tools, that address different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes and gene fragments, Oligonucleotide, or Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2.